IMforte: NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- CTD
- Dec 31, 2025
- 1 min read
Updated: Feb 1
First Posted | 2021-10-25 |
Trial status | Active, not recruiting |
Sponsor | Hoffmann-La Roche |
Abstract Presentation | Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
|
Peer-reviewed journal publication | Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 14
Click here for details
|
Press Release | Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer June 02, 2025 |
FDA | FDA Approved FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer October, 02, 2025 |
NCCN |
IMforte: NCT05091567: Phase 3: Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
(A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte))
Official Title: |
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab |
Intervention / Treatment: |
Drug: Atezolizumab Drug: Lurbinectedin Drug: Carboplatin Drug: Etoposide |
Other Study ID Numbers: |
GO43104 2023-503868-16-00 |
ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT05091567 |